pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

18 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1155Endpoints872BioPharma Dive339BioSpace293Fierce Biotech275onclive165raps104globenewswire health73
therapy area
allOncology7300Rare Disease1817Cardiology1644Immunology1449Hematology1292Vaccines1172Pulmonology1080Psychiatry & CNS
  • K Health plans IPO by 2029 after recent funding round
    K Health, a virtual‑care company that uses AI, announced its intention to go public by 2029. CEO Allon Bloch made the comment after a recent fundraising round, signalling the firm is preparing for…
    Endpoints · 5d agoPositive↗ source
  • Bausch + Lomb to launch Phase 3 trial of dry‑eye drop after Phase 2 miss
    Bausch + Lomb announced plans to move its dual‑action dry‑eye drop into a Phase 3 study. The decision follows a Phase 2 trial that did not meet its primary endpoint. CEO Brent Saunders said the r…
    Endpoints · 13d agoNegative readoutNeutral↗ source
fda recalls68
fda medwatch59
fda press38
856
Ophthalmology490
Pain464
Endocrinology & Metabolism459
Infectious Disease437
  • EyePoint’s Phase 3 eye drug falls short of Eylea, stock tumbles 70%
    EyePoint reported that its experimental treatment for wet age-related macular degeneration did not meet the efficacy endpoints in a Phase 3 trial when compared with the current standard, Eylea. The…
    Endpoints · 20d agoNegative readoutNegative↗ source
  • Tarsus Pharma to spend $450M upfront acquiring Alkeus to expand its ophthalmology pipeline
    Tarsus Pharmaceuticals announced it will acquire Alkeus Pharmaceuticals, a Phase 3 biotech focused on a Stargardt disease drug, for an upfront payment of $450 million. The deal is intended to broad…
    Endpoints · 1mo agoDealPositive↗ source
  • Pfizer reports Phase 3 success for Litfulo in vitiligo trials; Braveheart and Attovia target $275M and $182M IPOs
    Pfizer announced that its experimental drug Litfulo achieved Phase 3 success in two separate studies targeting active and stable nonsegmental vitiligo, an autoimmune condition that causes loss of s…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Claris Bio secures $118 million to launch pivotal eye-drop trials next year
    Claris Bio announced a financing round that raised $118 million to move its investigational eye‑drop therapy forward. The capital will fund two pivotal Phase 3 studies slated to start next year, f…
    Endpoints · 1mo agoDealPositive↗ source
  • Yarrow goes public while Otsuka receives FDA approval for new ADHD medication
    Yarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the ass…
    Endpoints · 1mo agoApprovalPositive↗ source
  • Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and Biogen
    Lyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
    Endpoints · 1mo agoPositive↗ source
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 2mo agoDealNeutral↗ source
  • Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease
    Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
    Endpoints · 2mo agoDealPositive↗ source
  • Biopharma CEOs see soaring compensation, new analysis to be discussed live
    Endpoints News released the first installment of its annual biopharma compensation project, breaking down the pay of the industry’s highest-earning CEOs. The company will host a Post-Hoc Live web…
    Endpoints · 2mo agoNeutral↗ source
  • Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidates
    Cavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
    Endpoints · 3mo agoDealPositive↗ source
  • Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumble
    Oculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Abeona shifts from eye gene therapy to solid tumor T‑cell programs as AstraZeneca’s rare disease drug clears Phase 3
    Abeona Therapeutics announced it is ending its eye‑focused gene‑therapy projects and will redirect resources toward developing T‑cell based treatments for solid tumors. The company says the pivot…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Astellas touts data from early test of stem cell-derived eye therapy
    Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The e…
    Endpoints · 4mo ago↗ source
  • Bayer to buy Perfuse Therapeutics for $300M upfront
    Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…
    Endpoints · 4mo ago↗ source
  • Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
    A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…
    Endpoints · 4mo ago↗ source
  • Biotech has a new startup model: Small team, big check and Chinese assets
    A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…
    Endpoints · 4mo ago↗ source